PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC 50 of 8.7 nM In Vitro PDE9-IN-1 is excellent selectivity across PDE families. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Unilateral common carotid artery occlusion (UCCAO) mouse model Dosage: 2.5 and 5.0 mg/kg Administration: Oral administration; daily for 21 days Result: Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice. Form:Solid IC50& Target:PDE9A 8.7 nM (IC 50 )